siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells

BACKGROUND: Doxorubicin is an effective breast cancer drug but is hampered by a severe, dose-dependent toxicity. Concomitant administration of doxorubicin and another cancer drug may be able to sensitize tumor cells to the cytotoxicity of doxorubicin and lowers the therapeutic dosage. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Xuejun, Liu, Anding, Zer, Cindy, Feng, Jianguo, Zhen, Zhuan, Yang, Mingfeng, Zhong, Li
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2691745/
https://www.ncbi.nlm.nih.gov/pubmed/19416503
http://dx.doi.org/10.1186/1471-2407-9-133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2691745/
https://www.ncbi.nlm.nih.gov/pubmed/19416503
http://dx.doi.org/10.1186/1471-2407-9-133

Ejemplares similares